These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 17626883)

  • 1. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
    Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
    Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
    Dbouk HA; Pang H; Fiser A; Backer JM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
    Hon WC; Berndt A; Williams RL
    Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.
    Ueki K; Algenstaedt P; Mauvais-Jarvis F; Kahn CR
    Mol Cell Biol; 2000 Nov; 20(21):8035-46. PubMed ID: 11027274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
    Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
    Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.
    Hale BG; Batty IH; Downes CP; Randall RE
    J Biol Chem; 2008 Jan; 283(3):1372-1380. PubMed ID: 18029356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
    Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
    Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
    Shekar SC; Wu H; Fu Z; Yip SC; Nagajyothi ; Cahill SM; Girvin ME; Backer JM
    J Biol Chem; 2005 Jul; 280(30):27850-5. PubMed ID: 15932879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein.
    Hale BG; Kerry PS; Jackson D; Precious BL; Gray A; Killip MJ; Randall RE; Russell RJ
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1954-9. PubMed ID: 20133840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
    Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling.
    Fu Z; Aronoff-Spencer E; Backer JM; Gerfen GJ
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3275-80. PubMed ID: 12629217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.